Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...
Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine. The ...
EST Moderna (MRNA) trading halted, volatility trading pauseMaximize Your Portfolio with Data Driven Insights:Leverage the power of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results